|
Central America Biotech News. Service for global professionals. Constantly updated news and information about Central America Biotech.
Latest Central America Biotech News
- FDA Approves Newly Revised Prescribing Information for Azilect Reducing Medication and Food Restrictions 18 Dec 2009 20:37 GMT
... (rasagiline tablets) is indicated for the treatment of ... 39 countries, including the U.S., Canada, Israel, Mexico and all of the European Union countries, ... pathway for the registration and approval of biotechnology-based products, the regulatory environment and changes in ...
- Pennystockchaser.com: www.pennnystockchaser.com: Penny Stock Chaser Alerts, December 18, 2009: KANA, GORO, OPTZ and PYMX 18 Dec 2009 19:13 GMT
... Pennystockchaser.com Alerts include KANA Software, Inc. (OTCBB: KANA); ... Aguila Project in the state of Oaxaca, Mexico. Commissioning of the El Aguila mill is ... Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious ...
- www.standoutstocks.com: Stocks That Stand Out For Dec. 18th, 2009 Are Dec 18, 2009 - avVaa World Health Care Products Inc. (Pink Sheets: AVVH), Dec 18, 2009 - Gold Resource Corporation (OTC Bulletin Board: GORO), Dec 17, 2009 - Ca 18 Dec 2009 17:04 GMT
... Dec 18, 2009 (M2 PRESSWIRE via COMTEX) -- www.Standoutstocks.com: Stocks That ... Aguila Project in the state of Oaxaca, Mexico. Commissioning of the El Aguila mill is ... heads of state of the Latin and Caribbean region to enhance the engineering profession for ...
- Upgrades & Downgrades: Is RIMM Ready to Run? 18 Dec 2009 15:00 GMT
... : Jefferies launches coverage of the biotech industry, including ) (Buy; $13). For more ... Hold. ): Food for thought at Chipotle Mexican Grill, now Neutral at Bank of America/ ...
- Amgen Receives CHMP Positive Opinion for Prolia(TM)... 18 Dec 2009 14:57 GMT
... onths) study in 7,868 women with postmenopausal osteoporosis ... osteoporosis in Europe, Australia, New Zealand and Mexico once the product is approved in these ... manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of ...
- NY GM engine plant to stop making "big block" V-8 18 Dec 2009 14:56 GMT
... NY GM engine plant to stop making "big block" ... 500 minicar, which will be made in Mexico and will go on sale in the ... reach to control the ability of new biotech firms to get wide distribution for their ...
- Amgen Receives CHMP Positive Opinion for Prolia (Denosumab) in the European Union 18 Dec 2009 14:46 GMT
... Amgen Receives CHMP Positive Opinion for Prolia (Denosumab) ... osteoporosis in Europe, Australia, New Zealand and Mexico once the product is approved in these ... manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of ...
- Amgen Receives CHMP Positive Opinion for Prolia(TM) (Denosumab) in the European Union 18 Dec 2009 12:31 GMT
... onths) study in 7,868 women with postmenopausal osteoporosis ... osteoporosis in Europe, Australia, New Zealand and Mexico once the product is approved in these ... manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of ...
- YM BioSciences, Therapure Biopharma Enter Into Service Contract 18 Dec 2009 05:17 GMT
... YM BioSciences, Therapure Biopharma Enter Into Service Contract For ... Europe for all activities and by Innogene Kalbiotech, YM's licensee in Southeast Asia, for global ... Brazil, China, India, Indonesia and, most recently, Mexico. David Allan said: "We have been very ...
- Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study 17 Dec 2009 23:41 GMT
... VANCOUVER, Dec. 17 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. ... outside of the United States, Canada and Mexico to vernakalant (iv) for rapid conversion of ... we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in ...
- Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite 17 Dec 2009 14:11 GMT
... - Therapure Biopharma to perform fill/finish of nimotuzumab - ... Europe for all activities and by Innogene Kalbiotech, YM's licensee in Southeast Asia, for global ... Brazil, China, India, Indonesia and, most recently, Mexico. In 2009, worldwide revenues for EGFR-targeting monoclonal ...
- Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 17 Dec 2009 12:47 GMT
... Therapure Biopharma Inc. and YM BioSciences Inc. Announce ... Europe for all activities and by Innogene Kalbiotech, YM's licensee in Southeast Asia, for global ... Brazil, China, India, Indonesia and, most recently, Mexico. In 2009, worldwide revenues for EGFR-targeting monoclonal ...
- YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract 17 Dec 2009 12:41 GMT
... - Therapure Biopharma to perform fill/finish of nimotuzumab - ... Europe for all activities and by Innogene Kalbiotech, YM's licensee in Southeast Asia, for global ... Brazil, China, India, Indonesia and, most recently, Mexico. In 2009, worldwide revenues for EGFR-targeting monoclonal ...
- YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract (CNW) 17 Dec 2009 12:41 GMT
... Nimotuzumab is a humanized monoclonal antibody that targets ... Brazil, China, India, Indonesia and, most recently, Mexico. In 2009, worldwide revenues for EGFR-targeting monoclonal ... Working closely with , another successful Canadian-based biotech company, has allowed us to meet their ...
- YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract (PRN) 17 Dec 2009 12:41 GMT
... Nimotuzumab is a humanized monoclonal antibody that targets ... Brazil, China, India, Indonesia and, most recently, Mexico. In 2009, worldwide revenues for EGFR-targeting monoclonal ... Working closely with , another successful Canadian-based biotech company, has allowed us to meet their ...
Powered by 
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>>
| |
|